TV50717-CNS-40223: The purpose of this study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a person’s quality of life.

CT-155-R-001: The purpose of this study is to investigate if digital therapeutics (a moblie software application) can help treat certain symptoms of schizophrenia. 

The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.